Anistreplase

Summary

Anistreplase (CHEMBL2108250) is an approved enzyme (ATC B01AD03); indicated across 1 condition including thrombotic disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• ATC class: B01AD03
• Indications: 1 condition

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108250
Name	Anistreplase
Type	Enzyme
Max phase	4
ATC	B01AD03

Also known as: Anistreplasa, Anistreplase, APSAC, BRL 26921, BRL-26921, Eminase, ANISTREPLASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
thrombotic disease	4	MONDO:0000831	HP:0004419

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).